Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: Diagnosing and monitoring pancreatic cancer through cell-free DNA methylation: progress and prospects

Fig. 1

Utility of blood-based liquid biopsy in diagnosis and management of pancreatic cancer. Circulating tumour cells (CTCs) and circulating cell-free DNA (cfDNA), stand as prominent biomarkers in liquid biopsy, providing non-invasive diagnostic, prognostic and therapeutic information. In particular, analysis of cfDNA can reveal tumor-causing genetics alterations, such as mutations, microsatellite instability (MSI), loss-of-heterozygosity (LOH), or aberrant methylation patterns. The mutated genes most frequently detected in cfDNA from pancreatic cancer patients are KRAS, TP53, APC, SMAD4 and FBXW7. Among the circulating biomarkers of methylation in pancreatic cancer are BNC1, NPTX2, SFRP1, RASSF1A and TFPI2

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us